文献速递心律失常高血压心力衰竭与心肌病

房颤筛查中缓慢心律失常的患病率与预后意义:LOOP随机试验事后分析

Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care: Post Hoc Analysis of the LOOP Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该事后分析基于LOOP随机临床试验,纳入6004例70岁以上无房颤但有心血管危险因素的受试者,比较植入式循环记录仪(ILR)筛查房颤与常规护理对缓慢心律失常诊断及预后的影响。中位随访65个月,ILR组缓慢心律失常诊断率显著高于对照组(20.8% vs 3.8%,HR 6.21),但晕厥和心源性猝死风险无显著差异。

要点

  • ILR筛查使缓慢心律失常诊断率提高6倍,多数无症状。
  • ILR组起搏器植入率显著增加(4.5% vs 2.9%,HR 1.53)。
  • 缓慢心律失常与后续晕厥、心血管死亡和全因死亡相关。

核心结论

  • 在70岁以上有心血管危险因素的人群中,长期连续监测房颤可使超过1/5者诊断缓慢心律失常。
  • ILR筛查较常规护理显著增加缓慢心律失常诊断和起搏器植入,但未改变晕厥或猝死风险。

研究设计与样本

  • LOOP随机临床试验的事后分析,在丹麦4个中心进行,2014年1月31日至2016年5月17日入组。
  • 共纳入6004例70岁以上无已知房颤但有高血压、糖尿病、心衰或既往卒中至少一项的受试者,随机分为ILR组(1501例)和对照组(4503例)。
  • 中位随访65个月(IQR 59-70),主要评估缓慢心律失常发作、起搏器植入、晕厥和心源性猝死。

主要发现

  • 无症状缓慢心律失常比例:对照组23.8%(41例) vs ILR组79.8%(249例)。

关键数值与推荐

  • 缓慢心律失常最常见类型为窦房结功能障碍,其次为高度房室传导阻滞。
  • 缓慢心律失常的危险因素包括较高年龄、男性和既往晕厥。
  • 缓慢心律失常与后续晕厥、心血管死亡和全因死亡相关,且与随机分组无交互作用。

临床怎么用

  • 对70岁以上有心血管危险因素者,长期连续监测可发现大量无症状缓慢心律失常。
  • ILR筛查增加起搏器植入,但未减少晕厥或猝死,需权衡筛查获益与过度诊断风险。

局限性

  • 为事后分析,结果需谨慎解释。
  • 缓慢心律失常的治疗由医生酌情决定,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is increasing interest in heart rhythm monitoring and technologies to detect subclinical atrial fibrillation (AF), which may lead to incidental diagnosis of bradyarrhythmias. OBJECTIVE: To assess bradyarrhythmia prevalence and prognostic significance in persons screened for AF using implantable loop recorder (ILR) compared with unscreened persons. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Implantable Loop Recorder Detection of Atrial Fibrillation to Prevent Stroke (LOOP) randomized clinical trial, which took place in 4 sites in Denmark. Participants were 70 years or older without known AF but diagnosed with at least 1 of the following: hypertension, diabetes, heart failure, or prior stroke. Participants were recruited by letter invitation between January 31, 2014, and May 17, 2016. The median (IQR) follow-up period was 65 (59-70) months. Analysis took place between February and June 2022. INTERVENTIONS: ILR screening for AF with treatment of any bradyarrhythmia left to the discretion of the treating physician (ILR group) vs usual care (control group). MAIN OUTCOMES AND MEASURES: Adjudicated bradyarrhythmia episodes, pacemaker implantation, syncope, and sudden cardiovascular death. RESULTS: A total of 6004 participants were randomized (mean [SD] age, 75 [4.1] years; 2837 [47.3%] female; 5444 [90.7%] with hypertension; 1224 [20.4%] with prior syncope), 4503 to control and 1501 to ILR. Bradyarrhythmia was diagnosed in 172 participants (3.8%) in the control group vs 312 participants (20.8%) in the ILR group (hazard ratio [HR], 6.21 [95% CI, 5.15-7.48]; P < .001), and these were asymptomatic in 41 participants (23.8%) vs 249 participants (79.8%), respectively. The most common bradyarrhythmia was sinus node dysfunction followed by high-grade atrioventricular block. Risk factors for bradyarrhythmia included higher age, male sex, and prior syncope. A pacemaker was implanted in 132 participants (2.9%) vs 67 (4.5%) (HR, 1.53 [95% CI, 1.14-2.06]; P < .001), syncope occurred in 120 (2.7%) vs 33 (2.2%) (HR, 0.83 [95% CI, 0.56-1.22]; P = .34), and sudden cardiovascular death occurred in 49 (1.1%) vs 18 (1.2%) (HR, 1.11 [95% CI, 0.64-1.90]; P = .71) in the control and ILR groups, respectively. Bradyarrhythmias were associated with subsequent syncope, cardiovascular death, and all-cause death, with no interaction between bradyarrhythmia and randomization group. CONCLUSIONS AND RELEVANCE: More than 1 in 5 persons older than 70 years with cardiovascular risk factors can be diagnosed with bradyarrhythmias when long-term continous monitoring for AF is applied. In this study, ILR screening led to a 6-fold increase in bradyarrhythmia diagnoses and a significant increase in pacemaker implantations compared with usual care but no change in the risk of syncope or sudden death.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Diederichsen, Xing, Frodi, et al. Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care: Post Hoc Analysis of the LOOP Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 36790817. doi:10.1001/jamacardio.2022.5526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。